Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The latest research publication added to our repository unveils a significant ascent within the Immuno-oncology Clinical Trials Market, with estimations forecasting the market size to amplify to USD 12.87 billion by 2030. Observing a resilient compound annual growth rate of 11.17%, this comprehensive market research report propounds a granular analysis of the industry's progressive trajectory from a valuation of USD 6.13 billion in 2023 to an anticipated peak in 2030.
Key Insights into Market Dynamics and Competitive Landscape
The research provides an extensive review of the market's dynamics, including an in-depth Market Share Analysis, which reveals insightful details concerning the current performance and standing of prominent vendors in the Immuno-oncology Clinical Trials sector. The evaluation offers a distilled perspective on the vendors’ contributions in terms of revenue generation, customer base expansion, and critical business metrics, thereby equipping companies with the strategic intelligence necessary to navigate the market's competitive waters.
Market Segmentation and Regional Prospects
As part of a thorough segmentation and coverage analysis, the research report dissects the Immuno-oncology Clinical Trials Market across numerous sub-markets and indications, such as hematological cancers and solid tumors, while considering various trial designs and phases. It also presents an evaluation of regional segments including North America, the Asia-Pacific region, and Europe, Middle East & Africa (EMEA), identifying regions and markets with substantial growth prospects.
Key Profiles and Developmental Insights
The report spotlights pivotal developments and the profiles of key industry vendors, encompassing trailblazers such as AstraZeneca, BioNTech, and Bristol Myers Squibb, among others. These profiles offer invaluable understanding into each vendor’s market presence and highlight contributions to innovating the immuno-oncology clinical trials landscape.
Companies Mentioned
- AstraZeneca PLC
- BioNTech SE
- Bristol Myers Squibb Company
- Exscientia PLC
- F. Hoffmann-La Roche Ltd.
- ICON PLC
- IO Biotech ApS
- IQVIA Inc.
- Laboratory Corporation of America Holdings
- Medpace, Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Rubius Therapeutics, Inc.
- Syneos Health, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/x8wgl9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
